Jay L. Patel, MD, MBA

Professor (Clinical), University of Utah School of Medicine

Specialties 

• Molecular diagnostics

Education

• Master’s Degree—Business Administration, University of Utah
• Medical Degree—University of Arizona
• Residency—Anatomic and Clinical Pathology, University of Utah
• Fellowship—Hematopathology, Stanford University

Certification/Affiliations

• American Board of Pathology (Anatomic and Clinical Pathology, Hematology)

Research Interests

• Application of next generation sequencing technologies in hematologic malignancies

Recent Publications

• Li P, Alnoor FNU, Xie W, et al. Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS. Leukemia. 2025;39(1):248-256.
• Kaur A, Rojek AE, Symes E, et al. Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024;14(1):99.
• Krah NM, Miotke L, Li P, et al. JAK2 R683S mutation resulting in dual diagnoses of chronic eosinophilic leukemia and myelodysplastic/myeloproliferative overlap syndrome. J Natl Compr Canc Netw. 2023;21(12):1218-1223.
• Patel JL, Erba HP, Savona MR, et al. Genomic data heterogeneity across molecular diagnostic laboratories: a real-world connect myeloid disease registry perspective on variabilities in genomic assay methodology and reporting. J Mol Diagn. 2023;25(8):611-618.
• Tomlinson B, de Lima M, Cogle CR, et al. Transplant referral patterns for patients with newly diagnosed higher-risk myelodysplastic syndromes and acute myeloid leukemia at academic and community sites in the Connect^® Myeloid Disease Registry: potential barriers to care. Transplant Cell Ther. 2023;29(7):460.e1-460.e9.
• Shomali W, Colucci P, George TI, et al. Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group. Leukemia. 2023;37(5):981-987.
• Agarwal AM, McMurty V, Clayton AL, et al. Clinical utility of targeted next-generation sequencing panel in routine diagnosis of hereditary hemolytic anemia: a national reference laboratory experience. Eur J Haematol. 2023;110(6):688-695.
• Suknuntha K, Geyer JT, Patel KP, et al. Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation. Leuk Res. 2023;127:107033.
• Sande CM, Wu R, Yang G, et al. Rapid and automated semiconductor-based next-generation sequencing for simultaneous detection of somatic DNA and RNA aberrations in myeloid neoplasms. J Mol Diagn. 2023;25(2):87-93.
• Li P, Brown S, Williams M, et al. The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms. Blood. 2022;140(7):716-755.
• Hu B, Patel JL, Tao R, et al. Near complete response to trametinib treatment in histiocytic sarcoma harboring a somatic KRAS mutation. J Natl Compr Canc Netw. 2022;20(6):618-621.
• Li P, White T, Xie W, et al. AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome. Leukemia. 2022;36(3):664-674.
• Osman A, Patel JL. Diagnostic challenge and clinical dilemma: the long reach of clonal hematopoiesis. Clin Chem. 2021;67(8):1062-1070.